The introduction of generic drugs, which have a chemically identical active ingredient to a brand-name drug on which patent protection has expired, has saved enormous amounts of money on drug spending. Over 85% of all prescriptions are now for generics. Biosimilars are intended to provide a generic for biologic therapies. But since those products are more complex, the cost and process for developing them is higher. And of course the drug companies are playing their usual games to prevent competition. A brief from the Pacific Research Institute’s Center for Medical Economics and Innovation explores potential savings if there was greater use of biosimilars. (Pac. Res. Paper) Off a baseline of all original biologic use, currently we are saving about $250 million through use of biosimilars. There are only 9 current therapies where a biosimilar is approved. If just for those categories, biosimilar use rose to 25%, we would save $2.5 billion, at 50% $4.8 billion and at 75%, $7.2 billion. While there may be clinical reasons why biosimilar usage would not be 100%, it should get close to that. And if biosimilar use grows dramatically, prices for those biosimilars should come down, providing even greater savings. Biosimilar development has been thwarted by drug company lobbying and lawsuits and by payoffs to biosimilar developers. Congress and the FDA need to take stronger action to facilitate, even subsidize biosimilar development and to allow payers to require their use except when clinically inappropriate. Europe has been much more aggressive in approving biosimilars and has reaped substantial savings. We should do the same.
How Much Money Would More Use of Biosimilars Save?
By Kevin RocheJuly 19, 2019Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 27, 2023
Why You Can’t Trust People Who Make Up Stuff About Vax Safety
A couple of studies offer a far better explanation for heart issues in athletes and…
March 25, 2023
Coronamonomania Lives Forever, Part 201
Tired of March Madness? A boringly refreshing dip into some CV-19 research summaries is recommended.
March 24, 2023
The CDC Is a Font of Methodological and Statistical Error
Several times in the last three years I and others have pointed out serious flaws…